|1.||Lipton, Allan: 31 articles (07/2012 - 01/2002)|
|2.||Saad, Fred: 30 articles (11/2015 - 01/2002)|
|3.||Coleman, Robert E: 28 articles (02/2014 - 01/2002)|
|4.||Adami, Silvano: 22 articles (11/2015 - 08/2003)|
|5.||Terpos, Evangelos: 22 articles (01/2015 - 01/2003)|
|6.||Body, Jean-Jacques: 22 articles (07/2011 - 02/2002)|
|7.||Clézardin, Philippe: 21 articles (11/2015 - 11/2002)|
|8.||Clemons, Mark: 21 articles (06/2015 - 01/2004)|
|9.||Reginster, Jean-Yves: 20 articles (06/2014 - 08/2005)|
|10.||Miller, Paul D: 20 articles (10/2013 - 10/2002)|
01/01/2013 - "The amino-bisphosphonates are first-line therapy for the treatment of most patients with osteoporosis, with proven efficacy to reduce fracture risk at the spine, hip, and other nonvertebral skeletal sites. "
11/01/2011 - "Outcomes showed that, relative to no treatment, treatment with oral bisphosphonates was predicted to be cost saving for most women aged ≥70 years with osteoporosis or at least one risk factor for fracture, and cost effective for women aged ≥75 years without prior fracture when used as a component of a population-based screen-and-treat programme. "
01/01/2011 - "Bisphosphonates, highly effective in the treatment of adults with osteoporosis, have also been used in children with secondary osteoporosis. "
01/01/2011 - "Bisphosphonates (BPs) are the most widely used and effective treatment for osteoporosis and Paget's disease. "
01/01/2010 - "Bisphosphonates are the most commonly used treatment for osteoporosis and have proven efficacy in the reduction of vertebral and nonvertebral fractures. "
|2.||Neoplasm Metastasis (Metastasis)
06/01/2008 - "Bisphosphonates are the most effective agent for treating and (or) preventing complications of bone metastasis, reducing the incidence of skeletal-related events, and improving quality of life in patients with bone metastasis."
01/01/2008 - "Bisphosphonates, which inhibit excessive osteoclast activity caused by ADT and bone metastases, have proven to be safe and effective in preventing skeletal complications and presently are the standard of care in patients with metastatic disease. "
12/01/2007 - "Bisphosphonates have proven efficacy in reducing and delaying skeletal-related events in patients with bone metastases, and play a key role in preserving patient functional independence and quality of life. "
05/01/2004 - "Bisphosphonates are potent inhibitors of osteoclast activity that have demonstrated efficacy in the treatment of bone metastases. "
01/01/2004 - "There has been a marked improvement in the time between the diagnosis of bone metastases and the commencement of bisphosphonates from a median of 155 days in 1998 to 24 days in 2001. "
12/01/1996 - "Bisphosphonates have proven to be effective in the treatment of tumor-induced hypercalcaemia. "
12/16/2014 - "In parallel, oral gavage with bisphosphonates of mice xenografted with HCC827 or MB231 cells led to a significant reduction in tumor volume in both treatment and prevention protocols. "
01/01/2014 - "To evaluate the long-term tolerance of bisphosphonates proposed as an alternative therapeutic option for symptomatic unresectable benign bone tumors and to evaluate the long-term efficacy of this treatment. "
04/01/2010 - "Bisphosphonates are effective in treatment and prevention of cancer treatment-induced bone loss, but their value in the prevention of fractures is still investigational. "
01/01/2010 - "In line with this, bisphosphonates are demonstrated to be particularly effective at reducing breast tumour growth when used in combination with agents that directly target cancer cells. "
07/01/2012 - "The antireabsorptive action of bisphosphonates has been considered the most effective in the disorders characterized by an excessive bone resorption. "
01/01/2005 - "Bisphosphonates are proven to be effective in the treatment of benign or malignant skeletal diseases characterized by enhanced osteoclastic bone resorption. "
01/01/2004 - "Bisphosphonates have been used effectively in adults and children to treat other bone disorders, since they have been proven to increase bone density through inhibition of bone resorption. "
09/01/1998 - "Bisphosphonates (BPs) are potent inhibitors of bone resorption and are therapeutically effective in disease of increased bone turnover, but their mechanism(s) of action remain to be elucidated. "
10/01/1993 - "The general availability of an ever-expanding range of increasingly potent bisphosphonates has resulted in a dramatic improvement in the treatment of increased bone resorption associated with malignancy. "
04/01/2012 - "Potent bisphosphonates are the cornerstone of current therapy and have been shown to produce biochemical remission, radiographic healing, pain relief and an improved quality of life. "
12/01/2003 - "The results are in favor of an efficacy of bisphosphonates in bone pain, even when not always statistically significant and with an important variability in assessment criterias and tools. "
10/01/2003 - "Bisphosphonates have proven to be effective in patients with fibrous dysplasia of the bone (FD) as shown by their effect on bone pain, markers of bone turnover, or radiological changes. "
01/01/2013 - "However, 8 trials (61.5%) reported that bisphosphonates improve pain assessed by VAS scores and 2 (38.5%) reported significant improvement in WOMAC pain scores compared to control groups. "
01/01/2012 - "Compared with placebo or no bisphosphonates, treatment with bisphosphonates significantly improved bone pain in six out of eleven studies. "
|1.||zoledronic acid (zoledronate)
|4.||Alendronate (Alendronate Sodium)
|5.||Calcitonin (Calcitonin, Eel)
|8.||risedronic acid (risedronate)
|1.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|4.||Hormone Replacement Therapy (Therapy, Hormone Replacement)